Regeneron announces an additional $350 million investment and 200 new jobs in Limerick by end-2017
Raheen site will be largest capacity biopharmaceutical production facility in Ireland.
Regeneron Pharmaceuticals is investing an additional $350 million in its Limerick Industrial Operations and Product Supply (IOPS) bioprocessing campus and will add another 200 jobs, bringing the total expected job creation in the Limerick area to 500 jobs and total investment to $650 million by the end of 2017.
The company acquired the former Dell Computer facility in Limerick and achieved planning approval in April 2014 for its first IOPS site outside of the US. When the investment was initially announced in December 2013, a $300 million investment with 300 jobs was planned for delivery by the end of 2016. With this expansion of scope, the Limerick IOPS campus will house the largest-scale bulk biologics production facility in Ireland.
With approximately 300 full-time employees, 200 contingent workers and 550 construction workers in place, recruitment is underway to bring on additional full-time, high-end specialist jobs in commercial manufacturing, process sciences, quality assurance/control and various support functions for scientists, chemists and technicians. At peak, 1200 contractors were onsite to support development.
Leonard S. Schleifer, President and CEO of Regeneron, said: "With a growing portfolio of marketed medicines and an innovative pipeline rooted in cutting-edge science and technology, Regeneron is one of the fastest-growing global biopharmaceutical companies. The Limerick facility will play an essential role in ensuring Regeneron delivers on our mission to consistently and repeatedly bring new medicines to patients with serious diseases."
Dan Van Plew, Senior Vice President and General Manager of IOPS at Regeneron, said: "The entire community has gone out of its way to welcome us and help us create the momentum we need to build this site. Our people — your countrymen — have done something remarkable. In less than 2 years we have brought a dormant building back to life, and are well on our way to building a complex, high-quality facility in industry-leading time. Our hundreds of current employees, contractors and trades people are top notch. The decision to create 200 new full-time roles and invest an additional $350 million in Limerick was an easy one to make because of our hiring and trades experiences over the last two years. Regeneron is an exciting company with excellent career opportunities. We are growing, and we need talented people to join us in creating something truly special here in Limerick."
Regeneron's 400,000-sq ft, state-of-the-art biologics production facility in Limerick is now operational with the first production line on track to enter validation before year end 2015. Regeneron has worked closely with the Department of Jobs and IDA Ireland on the development of its operations in Ireland.
In addition to IOPS' significant operations in Limerick, Regeneron also has a growing multi-functional team in Dublin supporting its business in Europe. Regeneron's total headcount in Ireland is expected to approach 550 by the end of 2017.
Related News
-
News WuXi to sell CGT manufacturing unit to US-based Altaris LLC
At the tail end of 2024, Chinese-based CDMO WuXi AppTec announced the signing of their deal with private equity firm Altaris LLC, confirming the sale of WuXi Advanced Therapies, the cell and gene therapy manufacturing arm of WuXi AppTec. -
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News CPHI Milan Wrap-Up Report: Conference Highlights
Discover the emerging and trending topics of the pharmaceutical industry with our CPHI Milan Conference Highlights, with exclusive insight from pharmaceutical leaders and experts! -
News BIOSECURE Act not included in key defense spending bill for 2025
On December 7, 2024, the Biden administration revealed the 2025 National Defense Authorization Act, an annual defense bill specifying the budget and expenditures of the US Department of Defense. The controversial BIOSECURE Act was notably missing from ... -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News Trump 2.0: What does the US election result mean for the healthcare industry?
After Trump won the Presidential election in the US in early November, we take a look at some of the implications a new Trump administration could have on the health and pharmaceutical industry, and on US patients. -
News Women in Pharma: Reflections from Behind the Scenes
In this instalment of our monthly series, the team that brings you the Women in Pharma series each month sits down for a heart-to-heart on what the series means to them, and how they hope to continue their work in the future. -
News Scaling the Industry: CPHI Scale-Up Market interview with YSK Laboratories
For the first time, CPHI Milan hosted the CPHI Start-Up Market, expanding support for emerging and small-sized enterprises in their transition to the next level of growth. In this interview, we spoke with Yuvansh Khokhani, Managing Director of YSK Labo...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance